Filtered By:
Condition: Stroke
Drug: Enalapril

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 61 results found since Jan 2013.

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Effect of folic acid supplementation on risk of new‐onset diabetes in adults with hypertension in China: Findings from the CSPPT
ConclusionsAmong adults with hypertension with no history of stroke and/or MI in China, folic acid supplementation had no significant effect on the risk of new‐onset diabetes. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes - October 11, 2015 Category: Endocrinology Authors: Xianhui Qin, Jianping Li, Yan Zhang, Dafang Chen, Binyan Wang, Mingli He, Jia Fu, Genfu Tang, Yefeng Cai, Xiuli Shi, Xin Xu, Fan Fan Hou, Xiaobin Wang, Yong Huo Tags: Original Article Source Type: research

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research

In Chinese adults with hypertension, adding folic acid to enalapril reduced incident stroke.
PMID: 26192588 [PubMed - in process]
Source: Annals of Internal Medicine - July 21, 2015 Category: Internal Medicine Authors: Barer D Tags: Ann Intern Med Source Type: research

Bioactive peptides identified in Thornback ray skin's gelatin hydrolysates by proteases from Bacillus subtilis and Bacillus amyloliquefaciens.
This study describes a peptidomic approach for the identification of ACE-inhibitory and antioxidant peptides generated from thornback ray muscle (Raja clavata) hydrolysates from Bacillus subtilis A26 and Bacillus amyloliquefaciens Neutrase® enzymes and expose the potential of thornback ray muscle hydrolysate as a source of bioactive peptides. In this sense, the decrease of systolic blood pressure is one of the main measurements considered in public health for the treatment of cardiovascular diseases, stroke and even end-stage renal disease. Traditionally, synthetic drugs such as captopril and enalapril have been used as A...
Source: Journal of Proteomics - July 4, 2015 Category: Biochemistry Authors: Lassoued I, Mora L, Barkia A, Aristoy MC, Nasri M, Toldrá F Tags: J Proteomics Source Type: research

In Context News in brief
Folic acid can reduce risk of first stroke, according to the results of a double-blind trial. 20 702 people with hypertension without a history of stroke or myocardial infarction enrolled in the China Stroke Primary Prevention Trial were randomly assigned to receive either combined enalapril 10 mg and folic acid 0·8 mg or enalapril 10 mg alone. The trial was terminated early, after a median of 4·5 years, when benefits of the combined treatment were identified: there was a significant reduction in risk of first stroke in the folic acid-enalapril group (hazard ratio 0·79, 95% CI 0·68–0·93) compared with enalapril alone group.
Source: Lancet Neurology - April 13, 2015 Category: Neurology Tags: In Context Source Type: research

Folic acid, a B vitamin, lowers stroke risk in people with high blood pressure
If you’re among the one in three American adults with high blood pressure, be sure you’re getting plenty of the B vitamin known as folate. Doing so may lower your odds of having a stroke, an often disabling or deadly event linked to high blood pressure, a new study suggests. Folate occurs naturally in many foods, but especially green leafy vegetables, beans, and citrus fruits. Here in the United States, add to the list most grain products, including wheat flour, cornmeal, pasta, and rice. They are fortified with the synthetic version of folate, known as folic acid. That’s not the case in many countries ar...
Source: New Harvard Health Information - March 18, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements Hypertension and Stroke high blood pressure Source Type: news

Folate Supplementation in HTN May Lower Risk for First StrokeFolate Supplementation in HTN May Lower Risk for First Stroke
Investigators from China say it's time to rethink the possible CV benefits of folic-acid supplementation: adding it to enalapril reduced risk of first stroke in hypertensive patients without CHD. Heartwire from Medscape
Source: Medscape Cardiology Headlines - March 16, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Folic acid supplementation among adults with hypertension reduces risk of stroke
(The JAMA Network Journals) In a study that included more than 20,000 adults in China with high blood pressure but without a history of stroke or heart attack, the combined use of the hypertension medication enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American College of Cardiology Annual Scientific Session.
Source: EurekAlert! - Medicine and Health - March 15, 2015 Category: Global & Universal Source Type: news

Folate Supplements for Stroke Prevention Targeted Trial Trumps the Rest
The effect of folate supplementation on cardiovascular disease has been studied in many observational studies and randomized trials and has been a topic of debate for a number of years. In this issue of JAMA, Huo and colleagues provide results from their important clinical trial of folic acid therapy for primary prevention of stroke. In a carefully designed and executed randomized trial, 20 702 adults with hypertension were randomized to receive enalapril alone (n = 10 354) or enalapril combined with 0.8 mg folic acid (n = 10 348). As recommended by the data and safety monitoring board, the trial was terminat...
Source: JAMA - Journal of the American Medical Association - March 15, 2015 Category: Journals (General) Source Type: research

Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China The CSPPT Randomized Clinical Trial
Conclusions and RelevanceAmong adults with hypertension in China without a history of stroke or MI, the combined use of enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke. These findings are consistent with benefits from folate use among adults with hypertension and low baseline folate levels.Trial Registrationclinicaltrials.gov Identifier: NCT00794885
Source: JAMA - Journal of the American Medical Association - March 15, 2015 Category: Journals (General) Source Type: research

Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia.
Abstract Patients with hypertension have a high risk of ischemic stroke and subsequent stroke-associated pneumonia. Stroke-associated pneumonia is most likely to develop in patients with dysphagia. The present study was designed to compare the ameliorative effects of different treatments in rat model of dysphagia. Spontaneously hypertensive rats were treated with bilateral common carotid artery occlusion (BCAO) to induce chronic cerebral hypoperfusion causing disorders of the swallowing reflex. Angiotensin-converting enzyme (ACE) inhibitors (perindopril, imidapril and enalapril), an angiotensin II type 1-receptor ...
Source: European Journal of Pharmacology - November 12, 2014 Category: Drugs & Pharmacology Authors: Ikeda JI, Kojima N, Saeki K, Ishihara M, Takayama M Tags: Eur J Pharmacol Source Type: research

Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model Kidney
Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spo...
Source: Hypertension - September 10, 2014 Category: Cardiology Authors: Griffin, K. A., Polichnowski, A., Litbarg, N., Picken, M., Venkatachalam, M. A., Bidani, A. K. Tags: Animal models of human disease Kidney Source Type: research

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling
Conclusions and ImplicationsA systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR was obtained in hypertensive and normotensive rats. This extended model can quantify dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using only HR and MAP measurements. Whether the model can be applied for compounds with a more complex MoA remains to be established.
Source: British Journal of Pharmacology - September 5, 2014 Category: Drugs & Pharmacology Authors: N Snelder, B A Ploeger, O Luttringer, D F Rigel, F Fu, M Beil, D R Stanski, M Danhof Tags: RESEARCH PAPER Source Type: research

Drug effects on the cardiovascular system in conscious rats – separating cardiac output into heart rate and stroke volume using PKPD modeling
Conclusions and ImplicationsA systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR has been obtained in hypertensive and normotensive rats. The extended model can be used to quantify the dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using HR and MAP measurements only. The question whether the model can also be applied for compounds with a more complex mechanism of action remains to be established.
Source: British Journal of Pharmacology - June 24, 2014 Category: Drugs & Pharmacology Authors: N. Snelder, B.A. Ploeger, O. Luttringer, D.F. Rigel, F. Fu, M. Beil, D.R. Stanski, M. Danhof Tags: Research Paper Source Type: research